Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes.
Amyloid
Amyloid tracer
Florbetapir
Multiple sclerosis
PET
White matter
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
24
07
2018
accepted:
25
09
2018
pubmed:
22
10
2018
medline:
8
5
2019
entrez:
22
10
2018
Statut:
ppublish
Résumé
The disease course of multiple sclerosis (MS) is unpredictable, and reliable prognostic biomarkers are needed. Positron emission tomography (PET) with β-amyloid tracers is a promising tool for evaluating white matter (WM) damage and repair. Our aim was to investigate amyloid uptake in damaged (DWM) and normal-appearing WM (NAWM) of MS patients, and to evaluate possible correlations between cerebrospinal fluid (CSF) β-amyloid Twelve MS patients were recruited and divided according to their disease activity into active and non-active groups. All participants underwent neurological examination, neuropsychological testing, lumbar puncture, brain magnetic resonance (MRI) imaging, and We found a lower SUV in DWM compared to NAWM (p < 0.001) in all patients. Decreased NAWM-SUV was observed in the active compared to non-active group (p < 0.05). Considering only active patients, NAWM volume correlated with NAWM-SUV (p = 0.01). Interestingly, CSF Aβ concentration was a predictor of both NAWM-SUV (r = 0.79; p = 0.01) and NAWM volume (r = 0.81, p = 0.01). The correlation between CSF Aβ levels and NAWM-SUV suggests that the predictive role of β-amyloid may be linked to early myelin damage and may reflect disease activity and clinical progression.
Identifiants
pubmed: 30343433
doi: 10.1007/s00259-018-4182-1
pii: 10.1007/s00259-018-4182-1
doi:
Substances chimiques
Amyloid beta-Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
280-287Commentaires et corrections
Type : CommentIn
Références
Exp Neurol. 2014 Dec;262 Pt A:2-7
pubmed: 24342027
Arch Neurol. 2011 Nov;68(11):1404-11
pubmed: 21747008
Neurol Sci. 2014 Jan;35(1):79-82
pubmed: 24101117
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Nat Rev Neurosci. 2008 Nov;9(11):839-55
pubmed: 18931697
Front Neurol. 2016 Mar 31;7:53
pubmed: 27065425
Eur J Neurol. 2015 Jun;22(6):981-9
pubmed: 25808578
Neuroimage. 2012 Feb 15;59(4):3774-83
pubmed: 22119648
Ann Neurol. 2011 Apr;69(4):673-80
pubmed: 21337603
Brain Pathol. 2011 May;21(3):263-78
pubmed: 21029240
BMC Neurol. 2015 Nov 25;15:243
pubmed: 26607782
Neurology. 1995 Feb;45(2):255-60
pubmed: 7854522
Presse Med. 2015 Apr;44(4 Pt 2):e159-67
pubmed: 25818312
N Engl J Med. 1998 Jan 29;338(5):278-85
pubmed: 9445407
Clin Chim Acta. 2015 Sep 20;449:23-30
pubmed: 25659291
Mult Scler. 2013 Apr;19(5):543-52
pubmed: 23069872
Glia. 1995 Oct;15(2):141-51
pubmed: 8567065
Neuroimage. 2014 Oct 15;100:684-691
pubmed: 24999038
Lancet Neurol. 2015 Feb;14(2):183-93
pubmed: 25772897
Nat Neurosci. 2006 Dec;9(12):1520-5
pubmed: 17099708
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):97-102
pubmed: 25331458
Mult Scler. 2019 Aug;25(9):1223-1231
pubmed: 30084711
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Curr Opin Neurol. 2017 Dec;30(6):608-616
pubmed: 28906268
Mult Scler. 2009 Apr;15(4):448-54
pubmed: 19153172
J Nucl Med. 2015 Sep;56(9):1408-14
pubmed: 26182970
Mult Scler. 2017 Jul;23(8):1085-1091
pubmed: 27754941
Neuropsychopharmacology. 2011 Feb;36(3):559-68
pubmed: 20944553
Ann Neurol. 2016 May;79(5):726-738
pubmed: 26891452